Gbola Amusa, MD, CFA Managing Director, Director of Research, Head of Healthcare Research at Chardan Capital Markets New York, New YorkFinancial Services Previous QMedica, UBS, Sanford C. Bernstein Education University of Chicago Graduate School of Business 500+ connectionsSend Gbola InMailMore options https://www.linkedin.com/in/gbolahanamusa Background Summary I am committed to working in the public's interest. Considering my whistleblowing case with UBS at the UK Tribunal, in Kit Chellel's article, despite Bloomberg (BB) policies, facts are omitted: - CFA Institute reviewed documents and reported no issues with my conduct - I downgraded Sanofi to Sell in Jan-09, not in Jun-09; there was no possibility of front-run ratings/estimate changes - No regulator has charged me with wrongdoing - The analyst who replaced me at UBS, and other analysts, in Jun-09 downgraded Sanofi and cut estimates, while I maintained mine; BB in Jun-09 attributed Sanofi price movements to multiple banks and wrote articles critical of Sanofi - Per UBS legal, Sanofi started the AMF investigation - The Tribunal confirmed that in 2010 I whistleblew on falsified UBS research - 2011: I reported harassment of my team by UBS when I downgraded a stock after a famous investor bought shares through UBS. Judge Glennie deemed the harassment a "nuisance"? not protected by the law - 2012: A senior UBS salesperson asked for unpublished research in exchange for client access; Judge Glennie deemed I did not report the criminal activity, despite the fact it occurred - UBS HR breached confidentiality, then the same Jan-13 day informed me of disciplinary matters - UBS used 2012/13 policy (written after I whistle-blew at UBS) to dismiss me for 2009 matters; Judge Glennie forgave this as an "error"? by UBS? - No 2009 policy was violated, yet Judge Glennie deemed fair the dismissal - Mr Whiting was part of management that did not escalate matters above - After 2010, my staffing was the lowest; Judge Glennie deemed it market conditions - My lawyer (also a Tribunal judge) went rogue at trial, gave the other side my documents, and argued my first whistle-blowing was in Jan-13 - UBS lawyers emailed me malware; UBS was in the Claimant's Tribunal room - Judge Glennie declined requests for dislosure of Jun-09 documents
I challenge BB to specify the "rumors"?/"information" cited. Why Whistleblowers Fail to Win in Europe Why Whistleblowers Fail to Win in Europe
Experience
Managing Director, Director of Research, Head of Healthcare Research Chardan Capital Markets 2014 – Present (2 years)New York City • Research franchise dedicated to covering leading companies levered to disruptive technologies (e.g. gene therapy) that will transform patient outcomes in the decade ahead STOCK PICKING (detail available on request) •2015: Generated an average alpha of 14% relative to the NBI on 25 published picks • 2015: 6 conviction picks generated an average alpha of 27% relative to the NBI • 2015: 5 of 5 Sell ratings were successful, with an average alpha versus the NBI of 45% • 2015: Top pick generated alpha versus the NBI of 42% • 2015: 10 of 20 Buy ratings were successful, with an average alpha versus the NBI of 6% • 10 of 10 on published pair trades, with an average alpha of 42% through 30-Jan-2016 SRI/ESG/SUSTAINABILITY • Selected as keynote speaker at the Biopharma Sustainability Roundtable 2015 and 2016 • Ongoing advocate for analysts being able to publish negative research without fear of retaliation Founding Principal QMedica 2013 – 2014 (1 year)Global • Adviser to respected healthcare start ups and think tanks located around the world • Developed financials, business plan, and financing/exit plan for a U.S personalized genomics healthcare start-up, thereafter tripling valuation in discussions with venture capitalists • Adviser to a U.S. patient-engagement solutions company, which was later sold in 2014 • Adviser to one of India’s largest medical information providers, which also provides free, open-source EMR systems benefiting patients throughout India, and thereafter the world Managing Director, Head of European Pharmaceuticals Research, Global Pharma/Biotech Coordinator UBS 2007 – 2013 (6 years)London, United Kingdom • Senior managing director at then the #1-#2 bank for European research • Global Pharma/Biotech Coordinator: Led c25 analysts in setting global therapeutics strategy • Clients: #1 analyst (of >100) in 2013 Institutional Investor (II) survey in unfractionated votes • Clients: #1 pharma team for European Investors in the 2012 Greenwich Associates survey • Trading: Finished 2012 as the #1 European sector at UBS in market share for commissions • Thought leadership: Published widely-read and successful anti-consensus calls, for example: WORLD PHARMA MODEL (2009): +160% ALPHA - 2009-Apr-20: In most important work (154 pages) as an analyst, chose Novo Nordisk, Novartis, Bayer as long-term Euro picks through the generics cliff; 6 years later (Apr-2009 to Apr-2015), the 3 outperformed the market and pharma by 160% STRATEGY (2009): SNY M&A; BMY & BIIB RECOMMENDED AS TARGETS - 2009-Jan-20: Foresaw the high amounts of acquisitions sell-rated Sanofi was to embark upon and recommended BMY and Biogen as the "most interesting assets" for Sanofi to buy (p 20) - Sanofi instead acquired GENZ and over 25 companies, and under-performed in the long term - 16-Jan-2009 to 16-Apr-2015 stock prices: BIIB +740%, BMY +271%, DRG +144%, SNY +110% M&A (2012): PFE FOR AZN; 2014 CONFIRMATION (+34% AZN ALPHA) - 3-May-2012: Argued AZN as a long-term M&A target; AZN outperformed on PFE's 2014 bid - 2-May-2012 to 30-May-2014: AZN +82%, DRG +48%, GSK +29% • Social responsibility/ESG: Research cited online by ATM Index, Shared Value Initiative/FSG, GMI Ratings; work acknowledged by the UBS Socially Responsible Investments (SRI) team - Acknowledged on page xii of the book "From Red to Green?: How the Financial Credit Crunch Could Bankrupt the Environment" • Stock picking: Rated as a top analyst in Bloomberg rankings (often #1) across rated stocks; several pharma Key Calls were top picks of all time for UBS Key Calls • Estimate accuracy: Previously maintained 99% performance in StarMine ratings Senior Research Analyst, Institutional Research, Head of European Pharmaceuticals Research Sanford C. Bernstein 2004 – 2007 (3 years)London, United Kingdom • Team leader on pharma franchise at Wall Street’s premier sell-side equity research firm • Client impact: #2 European pharma analyst by US investors in Institutional Investor (II) poll • Anti-consensus research led to some of the top trading days in the history of SCB London Associate Analyst, Institutional Research, European Pharmaceuticals Sanford C. Bernstein 2003 – 2004 (1 year)New York City, USA • Unprecedentedly promoted to Senior Research Analyst after <1 year as Associate Analyst Associate, Healthcare Group, Investment Banking Division Goldman Sachs 2001 – 2002 (1 year)New York City, USA • Produced analyses for Amgen/Immunex transaction, then the largest biotech acquisition in history • Modelled mergers, equity/debt underwritings, and raid defense advisory assignments Volunteer Experience & Causes
Opportunities Gbola is looking for: Joining a nonprofit board Certifications
Chartered Financial Analyst (CFA) Charterholder CFA Institute Starting 2002 Series 7, Series 24, Series 63, Series 86, Series 87Financial Industry Regulatory Authority (FINRA) Financial Industry Regulatory Authority (FINRA) Languages
English Native or bilingual proficiency Japanese Limited working proficiency Skills
Top Skills 24Valuation
18Investment Banking
12Capital Markets
11Equities
9Mergers & Acquisitions
6Equity Research
5Pharmaceutical Industry
5Emerging Markets
5Financial Modeling
4Private Equity
Gbola also knows about... 3Biotechnology Industry 3Investments 3Fixed Income 2Hedge Funds 1Investment Management 1Portfolio Management 1Investment Strategies 1Venture Capital Head of Pharmaceuticals... Global Pharmaceuticals... Healthcare Industry Healthcare Investment... Education
University of Chicago Graduate School of Business University of Chicago Graduate School of Business Master of Business Administration (MBA), Finance, Economics, Entrepreneurship, Strategy, High Honors (GPA 4.0/4.0) 1999 – 2001 Activities and Societies: Cohort Social Chair Washington University School of Medicine in St. Louis Washington University School of Medicine in St. Louis Doctor of Medicine (Medicinae Doctor) (MD), Medicine 1995 – 1999 Activities and Societies: Social Co-Chair Duke University Duke University Bachelor of Science in Engineering (BSE), Biomedical/Medical Engineering, Honors, National Science Foundation/ERC Fellow 1991 – 1995 Additional Info
Interests Photography, travel, Olympics, various sports
COVERAGE UNIVERSE of Charden Capital: chardancm.com/sites/all/modules/filefield/icons/protocons/16x16/mimetypes/application-pdf.png
*Dr. Navid Malik was appointed to the Board of Directors in April 2012. Dr. Malik is the Head of Life Sciences Research at Cenkos Securities Plc. in the U.K., an independent specialist institutional securities firm. From September 2011 through January 2012, Dr. Malik was the Head of Life Sciences Research at Sanlam (Merchant Securities), a global financial services firm. Dr. Malik was Partner and Head of Life Sciences at Matrix Investment Banking Division, Matrix Group, a financial services firm in London, from December 2008 through September 2011. Dr. Malik was a Senior Pharmaceuticals and Biotechnology Analyst at Wimmer Financial LLP from September 2008 through December 2008, and was the Senior Life Sciences Analyst at Collins Stewart Plc from January 2005 through September 2008. In 2011, Dr. Malik was awarded two Starmine Awards (awarded each year by Thomson Reuters and the Financial Times): Number One Stock Picker in the European Pharmaceutical Sector, and Number Two Stock Picker in the U.K. and Ireland Healthcare Sector. Dr. Malik holds a Ph.D. in Drug Delivery within Pharmaceutical Sciences, as well as degrees in Biomedical Sciences Research (M.Sc.) and Biochemistry and Physiology (B.Sc., joint honors). Dr. Malik also holds an MBA in finance from the City University Business School, London. We believe that Dr. Malik’s extensive experience in the life sciences fields and investment banking sector make him well qualified to serve as a Director.
DID Gbola recommend JAZZ @ the bottom?
In line with my commentary on UBS! and alumni@Sanford Bernstein. Similar to Gbola I issued a SELL recommendation where Merrill Lynch was the Investment Banker to a now bankrupt co that was $BLNS in revenue.
As for my massive portfolio changes and equity exposure one only needs look at: 1)ALL my GTATQ posts June 2015 re massive weakening in China; re AAPL 2)Late 2015 post interchange with ReadyforWHAT on Neil Woodford's corporate charter for his two funds which supports #1.
